Interestingly, there is previous evidence of inhibitory activity against LRRK2 for one of the top candidates: The anti-cancer drug Sunitinib is a receptor tyrosine kinase inhibitor that has been shown to efficiently inhibit LRRK2 [43]. Here, NTRK1 is linked to cancer.